Systemic therapy for sarcoidosis is reserved for organ-threatening disease, and laryngeal involvement necessitates treatment ...

The BOOG 2013-08 trial evaluates whether SLNB can be safely omitted for patients with clinically T1-2N0 treated with ...

The number of systemic anti-inflammatory therapies for dermatologic diseases in children is expected to grow in 2026.

New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx ...

For patients with advanced oropharyngeal cancer, proton therapy may beat photon radiotherapy in terms of overall survival and ...

Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this ...

The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

Company closed $22M financing to support randomized Phase 2b trial; IND cleared and study initiated; Interim results anticipated in late 2026; topline data expected in H2/2027 ...

ETX-19477 is a potent, selective inhibitor of poly (ADP-ribose) glycohydrolase (PARG), an enzyme that plays a role in the DNA ...

Adults with type 2 diabetes and cancer who used a GLP-1 had a lower risk for death and hospitalization compared with adults ...

A decade-long retrospective study shows IgG4-related cholangitis responds well to steroids, with low mortality and no ...